SEP 11, 2026 · PHASE 3 TRIAL
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
ClinicalTrials.gov
This is a Phase 3 registry record with no posted results; the study is actively enrolling and design facts only can be assessed.
Reported
Planned enrollment550
Study phasePhase 3
Primary outcome measureOverall Survival (OS)